

# NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been:

- accepted for use in the NHSScotland by the Scottish Medicines Consortium (SMC), and/or
- accepted for use by the NHS board's Area Drug and Therapeutics Committee (ADTC).

## How does the NHS board decide which new medicines to make available for patients?

Each NHS board has an ADTC. The ADTC is responsible for advising the NHS board on all aspects of the use of medicines. ADTCs take account of national and, where applicable, local guidance when deciding which medicines should be routinely available.

## What national guidance does the ADTC consider?

- SMC advises on the use of newly licensed medicines in NHSScotland. In the table, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example Healthcare Improvement Scotland provides advice on some health technology assessments, including National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs).

## What local guidance does the ADTC consider?

- Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each NHS board provide advice to their ADTCs on which medicines can be routinely used. Sometimes clinical experts decide that established medicines are a better choice than new medicines.
- Medicines routinely available for use within an NHS board are usually included in the 'local formulary'. The formulary is a list of medicines for use in the NHS board that has been agreed by ADTC in consultation with local clinical experts. The formulary encourages prescribers to become familiar with a limited list of medicines which can be used to treat the majority of medical conditions.

## What if a particular medicine is not routinely available in my NHS board?

- This is usually because the medicine has not been accepted by SMC for use in NHSScotland.
- There may also be differences in which medicines are preferred in NHS boards. If SMC accepts a number of medicines for which there are other medicines already available to treat a specific medical condition, the NHS board's decision may depend on clinical experts' preferences and experiences with the medicine in their local population and on local prescribing guidance. If a decision is made for a medicine not to be routinely prescribed, there are usually alternative medicines available on the formulary.
- If a medicine is not routinely available and there are no suitable formulary alternatives, a doctor can make a request to prescribe the medicine if they believe it will benefit an individual patient. All NHS boards have procedures in place to consider individual requests when a doctor considers that a medicine not included on the formulary would be the best treatment option for an individual patient.

The following table lists the NHS board's decisions on new medicines.

If you need more information on medicines decisions in your NHS board area, please email [hcis.adtc-collaborative@nhs.net](mailto:hcis.adtc-collaborative@nhs.net)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Adalimumab</b> injection Humira® 1209/16	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission</a>	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Adalimumab</b> injection Humira® 1208/16	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission</a>	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Alirocumab</b> pre-filled pen Praluent® 1147/16	adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent</a>	Available in line with local guidance for prescribing  10/10/2016	12/12/2016
<b>Cabazitaxel</b> infusion Jevtana® 735/11	In combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub</a>	Available in line with regional guidance for prescribing	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Canakinumab</b> injection Ilaris® 1210/16	Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_ilaris/canakinumab_ilaris_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_ilaris/canakinumab_ilaris_non_submission</a>	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Cefuroxime</b> intracameral injection Aprokam® 932/13	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated</a>	Available in line with national guidance	12/12/2016
<b>Dequalinium chloride</b> vaginal tablets Floumizin® 1194/16	Treatment of bacterial vaginosis.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin</a>	Available in line with national guidance	12/12/2016
<b>Fampridine</b> prolonged-release tablets Fampyra® 789/12	For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra</a>	Not available as not recommended for use in NHSScotland	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fentanyl</b> transdermal system  Ionsys®  1207/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission</a>	Management of acute moderate to severe post-operative pain in adult patients	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Ferric maltol</b> capsules  Feraccru®  1202/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru</a>	Treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD).	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Hydrocortisone</b> modified-release tablets  Plenadren®  848/12  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren</a>	Treatment of adrenal insufficiency in adults	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Idelalisib</b> tablets  Zydelig®  1212/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission</a>	In combination with ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy, or first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	Not available as not recommended for use in NHSScotland	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Insulin Glargine 300 units/ml</b> pre-filled pen Toujeo® 1078/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB</a>	Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above.	Available in line with local guidance for prescribing	12/12/2016
<b>Ivacaftor</b> tablets Kalydeco® 1193/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1193_16_ivacaftor_Kalydeco/ivacaftor_Kalydeco">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1193_16_ivacaftor_Kalydeco/ivacaftor_Kalydeco</a>	Treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Lenalidomide</b> capsules Revlimid® 1211/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission</a>	Treatment of adult patients with relapsed or refractory mantle cell lymphoma.	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Migalastat</b> capsules Galafold® 1196/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold</a>	Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease ( $\alpha$ -galactosidase A deficiency) and who have an amenable mutation.	Available in line with national guidance	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Nivolumab</b> infusion Opdivo® 1187/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo</a>	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Available in line with regional guidance for prescribing	12/12/2016
<b>Nivolumab</b> infusion Opdivo® 1188/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo</a>	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Olaparib</b> capsules Lynparza® 1047/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission</a>	Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.	Available in line with regional guidance for prescribing	12/12/2016
<b>Pegaspargase</b> injection/infusion Oncaspar® 1197/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar</a>	As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.	Available in line with regional guidance for prescribing	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b> infusion Keytruda® 1087/15	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub</a>	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Pertuzumab</b> infusion Perjeta® 1121/16	In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub</a>	Not available as not recommended for use in NHSScotland	12/12/2016
<b>Sofosbuvir and Velpatasvir</b> tablets Epclusa® 1195/16	Treatment of chronic hepatitis C virus (HCV) infection in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa</a>	Available in line with national guidance	12/12/2016